论文部分内容阅读
美国Smithkline Eeecham(SKB)和Genelabs公司已建立一项历时3年的合作项目,以研制并销售戊型肝炎疫苗。Genelabs公司将获得在亚洲部分地区共同销售和制备该疫苗的权利,SKB公司将获得其余地区专卖权。这项合作还包括研制丙型肝炎疫苗,已知丙型肝炎病毒会引起急、慢性输血后肝炎并导致肝癌。
U.S. Smithkline Eeecham (SKB) and Genelabs have set up a three-year partnership to develop and sell hepatitis E vaccine. Genelabs will have the right to co-market and prepare the vaccine in parts of Asia and SKB will acquire the remaining regional monopoly. The collaboration also includes the development of hepatitis C vaccine, which is known to cause acute and chronic posthepatic hepatitis and lead to liver cancer.